Boehringer Ingelheim Corporation's New Data to Show Viral Cure Rates in the Most Difficult to Treat Hepatitis C Patients  
4/5/2012 9:16:32 AM

INGELHEIM, Germany--(BUSINESS WIRE)--Key data from Boehringer Ingelheim’s hepatitis C virus (HCV) clinical trial programme, HCVersoTM, focusing on interferon-free treatment, has been selected for inclusion in the official European Association for the Study of the Liver (EASL) press office activities. These data are one of five abstracts from a range of new Boehringer Ingelheim HCV data that have been accepted for presentation at the International Liver Congress (ILC)TM 2012, taking place 18th– 22nd April in Barcelona, Spain.